Analysis on Clinical Characteristics and Prognosis of 47 Patients with Extranodal NK/T Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2021.01.014
- Author:
Qi-Hui LI
1
;
Ping YANG
1
;
Ji-Jun WANG
1
;
Fei DONG
1
;
Lei TIAN
1
;
Wei WAN
1
;
Xiao-Yan KE
1
;
Hong-Mei JING
2
Author Information
1. Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
2. Department of Hematology, Peking University Third Hospital, Beijing 100191, China,E-mail: hongmeijing@medmail.com.cn.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Disease-Free Survival;
Female;
Humans;
Lymphoma, Extranodal NK-T-Cell/therapy*;
Male;
Middle Aged;
Prognosis;
Retrospective Studies;
Survival Rate;
Transplantation, Autologous
- From:
Journal of Experimental Hematology
2021;29(1):86-90
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical features and prognostic factors of patients with extranodal NK/T cell lymphoma (ENKTL).
METHODS:The clinical data of patients with ENKTL from November 2009 to November 2019 was collected and retrospectively analyzed to clarify the clinical features of ENKTL, and evaluate the factors that affected survival and prognosis.
RESULTS:Forty-seven patients with ENKTL were collected, median age was 40 (12-82) years old, and more common in males than females, at the ratio of 1.47∶ 1. The median follow-up was 28 (1-112) months, and 5-year overall survival (OS) rate was 49.3%. The 5-year OS rates of the subjects with ECOG performance stage 0-1 and ≥2 were 51.6% and 0 (P=0.001), respectively. The 5-year OS rates of International Prognostic Index (IPI) score 0-1 and ≥2 were 60.0% and 40.6% (P=0.027), respectively. The 5-year OS rates of Ann Arbor staging Ⅰ/Ⅱ and stage Ⅲ/Ⅳ were 61.3% and 31.7% (P=0.005), respectively. The 5-year OS rates of the patients with presentation of B symptoms and without presentation of B symptoms were 79.0% and 30.1% (P=0.013), respectively. The 5-year OS rates of plasma EBV-DNA level < 5×10
CONCLUSION:ECOG score, B symptoms, the copy number of EBV-DNA, and treatment regimens are independent prognostic factors for OS of patients with ENKTL.
